Guest guest Posted December 26, 2009 Report Share Posted December 26, 2009 FTC Commissioner Pamela Harbour 14 Jun 2007 " The Competitive Implications of Generic Biologics " Excerpt: In simplest terms, biologics are drugs created from living cells, tissues, or organisms, through biologic processes. These drugs replicate natural biologic substances in our bodies, such as enzymes, antibodies, or hormones. Biologics are known as “large molecule” drugs, which means they typically are very complex in structure. Many of today’s " miracle " drugs are biologics. These drugs are used to treat cancer, immune disorders, and metabolic diseases. They drastically reduce disabling symptoms, and sometimes even save lives. Biologics require extremely sophisticated manufacturing techniques. Biologics manufacturers must program a living source to mass-produce a specific biological material. For example, scientists may use recombinant DNA technology to program instructions directly into the DNA of a cell. The cell will produce the desired protein, which can be harvested and used as a therapeutic drug or a diagnostic product. In contrast, traditional pharmaceutical drugs are " small molecule " compounds that are chemically synthesized, and usually consist of pure chemical substances. They are easier to manufacture, and they are also easier to analyze after they are manufactured. http://www.ftc.gov/speeches/harbour/070614genbio.pdf Not an MD Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.